Pharmacologic profiling reveals lapatinib as a novel antiviral against SARS-CoV-2 in vitro

The emergence of SARS-CoV-2 virus has resulted in a worldwide pandemic, but effective antiviral therapies are not widely available. To improve treatment options, we conducted a high-throughput screen to uncover compounds that block SARS-CoV-2 infection. A minimally pathogenic human betacoronavirus (...

Descripción completa

Detalles Bibliográficos
Autores principales: Raymonda, M.H., Ciesla, J.H., Monaghan, M., Leach, J., Asantewaa, G., Smorodintsev-Schiller, L.A., Lutz, M.M., Schafer, X.L., Takimoto, T., Dewhurst, S., Munger, J., Harris, I.S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8626825/
https://www.ncbi.nlm.nih.gov/pubmed/34871905
http://dx.doi.org/10.1016/j.virol.2021.11.008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8626825/
https://www.ncbi.nlm.nih.gov/pubmed/34871905
http://dx.doi.org/10.1016/j.virol.2021.11.008

Ejemplares similares